A review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis

The worldwide occurrence of community-acquired pneumonia (CAP) shows an undiminished prevalence of this serious illness and hospitalisation is common in those patients with severe illness. The diversity of bacterial pathogens that can act as aetiologic agents presents a challenge to initial empiric...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Antimicrobial Agents 1999-06, Vol.12 (1), p.5-17
Main Author: Finch, Roger G.
Format: Article
Language:English
Subjects:
Acute bacterial exacerbations
Acute Disease
Animals
Anti-Infective Agents - pharmacology
Anti-Infective Agents - therapeutic use
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial Infections - drug therapy
Biological and medical sciences
Bronchitis - drug therapy
Bronchitis - microbiology
Chronic Disease
Clinical Trials as Topic
Community-Acquired Infections - drug therapy
Community-Acquired Infections - microbiology
Community-acquired pneumonia
Fluoroquinolones
Haemophilus influenzae
Humans
Medical sciences
Moraxella catarrhalis
Pharmacology. Drug treatments
Pneumonia, Bacterial - drug therapy
Pneumonia, Bacterial - microbiology
Sparfloxacin
Streptococcus pneumoniae
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The worldwide occurrence of community-acquired pneumonia (CAP) shows an undiminished prevalence of this serious illness and hospitalisation is common in those patients with severe illness. The diversity of bacterial pathogens that can act as aetiologic agents presents a challenge to initial empiric antimicrobial management. In recent years, treatment has been further complicated by an increased incidence of antibiotic resistance in pathogens such as Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. The newly available fluoroquinolones including sparfloxacin offer an alternative approach to empiric management. Sparfloxacin is active against many typical and atypical pathogens, as well as strains resistant to conventional agents. In comparative studies, the in vitro potency of sparfloxacin and its pharmacokinetic profile have been confirmed. The clinical trial efficacy and safety data suggest it might be a useful empiric therapy for both CAP and acute bacterial exacerbation of chronic bronchitis.
ISSN:0924-8579
1872-7913
DOI:10.1016/S0924-8579(98)00090-9